Skip to main content
Pharmena S.A. logo

Pharmena S.A. — Investor Relations & Filings

Ticker · PHR ISIN · PLPHRMN00011 LEI · 259400RHT936BBKW0955 WAR Manufacturing
Open in API
Filings indexed 649 across all filing types
Latest filing 2020-11-25 AGM Information
Country PL Poland
Listing WAR PHR

About Pharmena S.A.

https://www.pharmena.eu/

Pharmena S.A. is a specialty healthcare company focused on the development and commercialization of innovative products based on its patented active ingredient, 1-MNA. This molecule is a naturally occurring metabolite of niacin (vitamin B3) that plays a crucial role in cellular metabolism. The company's technology leverages the ability of 1-MNA to optimize the levels of the coenzyme NAD+, which decline with age and are vital for cellular function and regeneration. The product portfolio includes specialized cosmeceuticals, such as the Dermena line for hair loss, and dietary supplements designed to address the effects of cellular aging.

Recent filings

Filing Released Lang Actions
Treść uchwał podjętych przez NWZ PHARMENA S.A. w dniu 24.11.2020 r. - Content (PL)
AGM Information Classification · 95% confidence The document text explicitly mentions the content of resolutions ('treść uchwał') passed during an Extraordinary General Meeting ('Nadzwyczajnego Walnego Zgromadzenia') held on November 5th and resumed on November 24th, 2020. This directly relates to the outcomes of a shareholder meeting. The closest specific category is AGM Information (AGM-R), which covers presentations and materials shared during the Annual General Meeting (AGM). Although this is an Extraordinary (Nadzwyczajne) meeting, AGM-R is the most appropriate category for formal meeting resolutions/materials among the provided options, as there is no specific code for EGM resolutions. The document is short and contains the core information, not just an announcement of publication.
2020-11-25 Polish
Pharmena_Raport za III kwartał 2020_signed
Interim / Quarterly Report Classification · 100% confidence The document is a table of contents and detailed structure for a 'Skonsolidowany Raport Kwartalny' (Consolidated Quarterly Report) for the period ending September 30, 2020. It contains comprehensive financial statements (balance sheet, income statement, cash flow, etc.) and detailed management notes. As it is a full quarterly financial report rather than an announcement or a summary, it is classified as an Interim/Quarterly Report. 9M 2020
2020-11-23 Polish
Rozpoczęcie badań przedklinicznych w celu ustalenia maksymalnej tolerowanej dawki 1-MNA, kandydata na lek w infekcji wirusem Sars-Cov-2 - Content (PL)
Regulatory Filings Classification · 95% confidence The document is a current report (Raport Bieżący) issued by the Management Board (Zarząd) of PHARMENA S.A. It provides an update on the commencement of preclinical trials for a drug candidate against Sars-Cov-2, referencing a previous report. It details the progress, the research organization (Covance Inc.), and the potential impact on the company's future activities. This type of announcement, updating on ongoing operational or research milestones, does not fit the specific categories like 10-K (Annual Report), ER (Earnings Release), or IP (Investor Presentation). Since it is a specific, material operational update that doesn't fit the other defined categories (like DIRS, DIV, CAP, etc.), the most appropriate fallback category is Regulatory Filings (RNS), which serves as a general category for miscellaneous regulatory announcements not covered elsewhere.
2020-11-17 Polish
Treść uchwały podjętej przez NWZ PHARMENA S.A. w dniu 05 11 2020
AGM Information Classification · 99% confidence The document text is titled "Uchwała podjęta przez Nadzwyczajne Walne Zgromadzenie" (Resolution adopted by the Extraordinary General Meeting) and details a specific resolution (Uchwała nr 1) regarding adjourning the meeting until a future date (November 24, 2020). This document explicitly records the results and decisions made during a shareholder meeting, including the vote counts ('za', 'przeciw', 'wstrzymujących się'). This directly corresponds to the definition of Declaration of Voting Results & Voting Rights Announcements (DVA), which covers official results from shareholder votes at any general meeting.
2020-11-06 Polish
Treść uchwały podjętej przez NWZ PHARMENA S.A. w dniu 05.11.2020 r. - Content (PL)
AGM Information Classification · 99% confidence The document text is very short (689 characters) and explicitly states that the Management Board ('Zarząd') is enclosing the content of a resolution ('treść uchwały') adopted by the Extraordinary General Meeting ('Nadzwyczajne Walne Zgromadzenie') held on November 5, 2020. This structure—announcing the results or content of a shareholder meeting resolution—strongly suggests a filing related to the outcome of a general meeting. The most fitting category is 'Declaration of Voting Results & Voting Rights Announcements' (DVA), as it concerns the official outcome of a shareholder vote. Although it mentions the resolution content is attached, the primary purpose is reporting the result of the vote taken at the EGM.
2020-11-06 Polish
201023_Powiadomienie o transakcji_zbycie akcji
Director's Dealing Classification · 100% confidence The document is titled "Powiadomienie o transakcji/transakcjach*, o którym mowa w art. 19 ust. 1 rozporządzenia MAR" (Notification of a transaction/transactions referred to in Article 19(1) of the MAR Regulation). It details the sale ('Zbycie') of shares ('akcje na okaziciela') in Pharmena Spółka Akcyjna by individuals closely associated with management ('Osoba blisko związana z osobami pełniącymi obowiązki zarządcze'). Article 19 of MAR (Market Abuse Regulation) mandates disclosures for transactions conducted by persons discharging managerial responsibilities (PDMRs) and persons closely associated with them. This specific type of insider transaction disclosure directly corresponds to the 'Director's Dealing' category.
2020-10-27 Polish

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.